https://www.selleckchem.com/products/smi-4a.html
ed on previous experiences with ropeginterferon alfa-2b and other forms of interferon. Ropeginterferon alfa-2b exposure was higher in Japanese subjects than in Caucasian subjects. The increase in ropeginterferon alfa-2b exposure was greater than the dose proportion in the dose range of 100-300 µg. Ropeginterferon alfa-2b was safe and well tolerated. ClinicalTrials.gov identifier NCT03546465, registered on 6 June, 2018. ClinicalTrials.gov identifier NCT03546465, registered on 6 June, 2018. Peficitinib, a Janus kinase (JAK) inhibitor, is a
Beğen
Yorum Yap
Paylaş
